company background image
VOR logo

Vor Biopharma NasdaqGS:VOR Stock Report

Last Price

US$0.87

Market Cap

US$60.1m

7D

-10.4%

1Y

-65.2%

Updated

24 Dec, 2024

Data

Company Financials +

Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$60.1m

VOR Stock Overview

Operates as a clinical-stage cell and genome engineering company. More details

VOR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 78.34% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($60M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Vor Biopharma Inc. Competitors

Immix Biopharma

NasdaqCM:IMMX

US$60.0m

Annovis Bio

NYSE:ANVS

US$69.1m

Vistagen Therapeutics

NasdaqCM:VTGN

US$71.0m

Burning Rock Biotech

NasdaqGM:BNR

US$67.5m

Price History & Performance

Summary of share price highs, lows and changes for Vor Biopharma
Historical stock prices
Current Share PriceUS$0.87
52 Week HighUS$3.14
52 Week LowUS$0.63
Beta-0.37
1 Month Change10.70%
3 Month Change15.07%
1 Year Change-65.16%
3 Year Change-92.47%
5 Year Changen/a
Change since IPO-97.67%

Recent News & Updates

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Dec 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Recent updates

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Dec 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

Shareholder Returns

VORUS BiotechsUS Market
7D-10.4%-3.3%-2.2%
1Y-65.2%-1.9%23.9%

Return vs Industry: VOR underperformed the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: VOR underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is VOR's price volatile compared to industry and market?
VOR volatility
VOR Average Weekly Movement12.3%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: VOR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VOR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015168Robert Angwww.vorbio.com

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML.

Vor Biopharma Inc. Fundamentals Summary

How do Vor Biopharma's earnings and revenue compare to its market cap?
VOR fundamental statistics
Market capUS$60.06m
Earnings (TTM)-US$112.46m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is VOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VOR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$112.46m
Earnings-US$112.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VOR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vor Biopharma Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.